Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 2536 AL 2550

Chemical structure informing statistical hypothesis testing in metabolomics

Zhu H, Luo M.

Bioinformatics. 2014 Feb 15;30(4):514-22. doi: 10.1093/bioinformatics/btt708. Epub 2013 Dec 5.

Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study

Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C.

Exp Gerontol. 2014 Feb;50:114-21. doi: 10.1016/j.exger.2013.12.001. Epub 2013 Dec 10.

Biomarker modeling of Alzheimer's disease

Jack CR Jr, Holtzman DM.

Neuron. 2013 Dec 18;80(6):1347-58. doi: 10.1016/j.neuron.2013.12.003.

A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative

Braskie MN, Thompson PM.

Biol Psychiatry. 2014 Apr 1;75(7):527-33. doi: 10.1016/j.biopsych.2013.11.020. Epub 2013 Nov 28.

CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility

Raj T, Ryan KJ, Replogle JM, Chibnik LB, Rosenkrantz L, Tang A, Rothamel K, Stranger BE, Bennett DA, Evans DA, De Jager PL, Bradshaw EM.

Hum Mol Genet. 2014 May 15;23(10):2729-36. doi: 10.1093/hmg/ddt666. Epub 2013 Dec 30.

Immunological aspects and anti-amyloid strategy for Alzheimer's dementia

Liščić RM.

Arh Hig Rada Toksikol. 2013 Dec;64(4):603-8. doi: 10.2478/10004-1254-64-2013-2414.

Amyloid precursor protein expression is enhanced in human platelets from subjects with Alzheimer's disease and frontotemporal lobar degeneration: a real-time PCR study

Vignini A, Morganti S, Salvolini E, Sartini D, Luzzi S, Fiorini R, Provinciali L, Di Primio R, Mazzanti L, Emanuelli M.

Exp Gerontol. 2013 Dec;48(12):1505-8.

Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study

Ellis KA, Rainey-Smith SR, Rembach A, Macaulay SL, Villemagne VL; AIBL Research Group.

Int Rev Psychiatry. 2013 Dec;25(6):699-710. doi: 10.3109/09540261.2013.870136.

Preventing cognitive decline in preclinical Alzheimer's disease

Riedel WJ.

Curr Opin Pharmacol. 2014 Feb;14:18-22. doi: 10.1016/j.coph.2013.10.002. Epub 2013 Nov 13.

Three-week nutritional supplementation effect on long-term nutritional status of patients with mild Alzheimer disease

de Sousa OL, Amaral TF.

Alzheimer Dis Assoc Disord. 2012 Apr-Jun;26(2):119-23. doi: 10.1097/WAD.0b013e31822c5bb3.

Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study

Hansson O, Stomrud E, Vanmechelen E, Östling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I.

J Alzheimers Dis. 2012;28(1):231-8. doi: 10.3233/JAD-2011-111418.

Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia

Nielsen HM, Palmqvist S, Minthon L, Londos E, Wennström M.

Curr Alzheimer Res. 2012 Mar;9(3):257-66. doi: 10.2174/156720512800107537.

Linking atherosclerosis to Alzheimer's disease: focus on biomarkers

Emanuele E, Martinelli V, Abbiati V, Ricevuti G.

Front Biosci (Elite Ed). 2012 Jan 1;4(2):700-10. doi: 10.2741/e411.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics

Bakulski KM, Rozek LS, Dolinoy DC, Paulson HL, Hu H.

Curr Alzheimer Res. 2012 Jun;9(5):563-73. doi: 10.2174/156720512800617991.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias